COMT inhibition: A new treatment strategy for Parkinson's disease

Neurology

Volumn 50, Issue 5 SUPPL. 5, 1998, Pages

  Kurth, Matthias C ^a   Adler, Charles H ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALANINE AMINOTRANSFERASE; AMINO ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; ASPARTATE AMINOTRANSFERASE; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DECARBOXYLASE INHIBITOR; DOPAMINE; ENTACAPONE; GALLIC ACID; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; OXIDOPAMINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE; TROPOLONE;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DYSKINESIA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0031923914     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.5_suppl_5.s3     Document Type: Article

References (38)

1. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17(suppl 2): S32-44.
2. Sage JI, Mark MH. Basic mechanisms of motor fluctuations. Neurology 1994;44(suppl 6):S10-14.
3. Juncos JL. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Neurol Clin 1992;10:487-509.
4. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
5. Olanow CW, Fahn S, Muenter M, et al. A multicenter, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease. Mov Disord 1994;9:40-47.
6. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:257-262.
7. Lees AJ, for the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
8. Rascol O. A double-blind L-dopa controlled study of ropinirole in patients with early Parkinson's disease [Abstract]. Neurology 1996;46(suppl 2):A160.
9. Männistö PT. Clinical potential of catechol-O-methyl-transferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994;1:172-179.
10. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuvants in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317-323.
11. Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994;25:813-824.
12. Da Prada M, Zürcher G, Kettler R, Dingemanse J, Jorga K, Dubuis R. Remodeling the kinetics of dynamics of levodopa therapy in Parkinson's disease by inhibiting MAO-B with lazabemide and COMT with tolcapone. In: Poewe W, Lees AJ, eds. Levodopa - the first 25 years. Basel: Editions Roche, 1993:99-117.
13. Nissinen E, Lindén I-B, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992;346:262-266.
14. Kaakkola S, Wurtman RJ. Effects of catechol-O-methyl-transferase inhibitors and L-3,4-dihydroxyphenyl-alanine with or without carbidopa on extra cellular-dopamine in rat striatum. J Neurochem 1993;60:137-144.
15. Keräenen T, Gordin A, Harjola V-P, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-156.
16. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
17. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55.
18. Dingemanse J, Jorga KM, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Pharmacol 1995;40: 253-262.
19. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-517.
20. Snow BJ, Vingerhoets FJP, Holde JE, et al. The effect of tolcapone on central and peripheral COMT activity in normal humans and Parkinson's disease: a PET study [Abstract]. Mov Disord 1996;2(Suppl 1):195.
21. Jorga KM, Dingemanse, J, Fotteler B, et al. Effect of a novel COMT inhibitor on L-dopa pharmacokinetics when combined with different Madopar® formulations [Abstract]. Neurology 1997;48(Suppl 3):274.
22. Jorga K. Effect of the novel COMT inhibitor tolcapone on L-dopa pharmacokinetics when combined with different Sinemet formulations [Abstract], Neurology 1995;45(Suppl 4): A291.
23. Jorga K, Dingemanse J, Fotteler J, Zürcher G. Pharmacokinetics-pharmacodynamics of a novel COMT inhibitor during multiple dosing regimens [Abstract]. Clin Pharmacol Ther 1993;53(suppl 2):II-40.
24. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994;44:2685-2688.
25. Kurth MC, Adler CH, Saint Hilaire M-H, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
26. Rajput AH, Martin W, Saint Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49:1066-1071.
27. Baas H, Beiske AG, Ghika J, et al., on behalf of the Study Investigators. COMT inhibition with tolcapone reduces "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
28. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-265.
29. Nutt JG, Woodward WR, Beckner RM. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
30. Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993;45:419-423.
31. Kaakkola S, Teräeväeinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
32. Merello M, Lees AJ, Webster R, Bovington M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
33. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996; 19:283-296.
34. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
35. Kieburtz K, Rinne UK. The COMT inhibitor entacapone increases "on" time in levodopa-treated PD patients with motor fluctuations: report of two randomized, placebo-controlled trials [Abstract]. Mov Disord 1996;11:595-596.
36. Waters CH, Kurth M, Bailey P, et al., and the Tolcapone Stable Study Group. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49: 665-671.
37. Agid Y, Destée A, Durig F, Montastruc J-L, Pollack P, on behalf of the French Tolcapone Study Group. Tolcapone, bromocriptine, and Parkinson's disease. Lancet 1997;350:712-713.
38. Jorga KM, Fotteler B. Clinical pharmacology of COMT-inhibitors: differences and similarities between entacapone and tolcapone [Abstract]. Acta Neurol Scand 1996;94(suppl 167):8.